SWOT Analysis for Mersana Therapeutics Inc

Price crossing above SMA20 today, and greater than SMA5
Stocks whose current price is 20% higher than week low, and more than previous close
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Increasing Revenue every quarter for the past 2 quarters
Annual Net Profits improving for last 2 years
Top Gainers
Stock with Low PE (PE < = 10)
Biggest Price Gainers from Open

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Lowest Momentum Scores (Technical Scores)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Highest fall from 52 Week High
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Book Value Per Share deteriorating for last 2 years
Weak performer : Stock lost more than 20% in 1 month
RSI indicating price weakness
Stocks Underperforming their Industry Price Change in the Quarter